Drug interactions in cancer therapy

Nature Reviews Cancer

Volumn 6, Issue 7, 2006, Pages 546-558

  Scripture, Charity D ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALTRETAMINE; ANTACID AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BUSULFAN; CAPECITABINE; CARBAMAZEPINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; HYPERICUM PERFORATUM EXTRACT; IMATINIB; IRINOTECAN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; PACLITAXEL; PENICILLIN DERIVATIVE; RECOMBINANT INTERLEUKIN 2; TENIPOSIDE; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVATION; FOOD DRUG INTERACTION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IN VITRO STUDY; NEUROTOXICITY; PREDICTION; PRIORITY JOURNAL; REVIEW; TOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; HUMANS; NEOPLASMS;

EID: 33745574979     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1887     Document Type: Review

References (150)

1. Kuhlmann, J. & Muck, W. Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Saf. 24, 715-725 (2001).
2. Singh, B. N. & Malhotra, B. K. Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clin. Pharmacokinet. 43, 1127-1156 (2004). A comprehensive review of the effects of food on the pharmacokinetics of anticancer agents.
3. Sparreboom, A., Cox, M. C., Acharya, M. R. & Figg, W. D. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J. Clin. Oncol. 22, 2489-503 (2004). Comprehensive review on the potential for adverse drug interactions with anticancer agents based on both preclinical and clinical evaluations.
4. Ando, Y. in Handbook of Anticancer Pharmacokinetics and Pharmacodynamics (eds W. D. Figg and H. L. McLeod) 215-230 (Humana Press, Totowa, USA, 2004).
5. Coulthard, S. A. & Boddy, A. V. in Handbook of Anticancer Pharmacokinetics and Pharmacodynamics (eds W. D. Figg and H. L. McLeod) 189-214 (Humana Press, Totowa, USA, 2004).
6. Scripture, C. D., Sparreboom, A. & Figg, W. D. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. 6, 780-789 (2005).
7. Weinshilboum, R. Inheritance and drug response. N. Engl. J. Med. 348, 529-537 (2003).
8. Evans, W. E. & McLeod, H. L. Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549 (2003). Weinshilboum and Evans provide an excellent discussion of pharmacogenomics and the effects of genetic variation on drug disposition and response.
9. Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037 (2001).
10. Demetri, G. D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472-480 (2002).
11. Adair, C. G., Bridges, J. M. & Desai, Z. R. Can food affect the bioavailability of chlorambucil in patients with haematological malignancies? Cancer Chemother. Pharmacol. 17, 99-102 (1986).
12. Gunnarsson, P. O., Davidsson, T., Andersson, S. B., Backman, C. & Johansson, S. A. Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur. J. Clin. Pharmacol. 38, 189-193 (1990).
13. Pharmacia & Upjohn Company. Emcyt prescribing information. Pfizer [online], http://www.pfizer.com/pfizer/download/uspi_emcyt.pdf (2003).
14. Reigner, B. et al. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin. Cancer Res. 4, 941-948 (1998).
15. Roche Laboratories Inc. Xeloda prescribing information. Roche [online], http://www.rocheusa.com/products/xeloda/pi.pdf (2005).
16. Zhang, Y. & Benet, L. Z. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 40, 159-168 (2001).
17. Bailey, D. G., Arnold, J. M. & Spence, J. D. Grapefruit juice and drugs. How significant is the interaction? Clin. Pharmacokinet. 26, 91-98 (1994).
18. He, K. et al. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem. Res. Toxicol. 11, 252-259 (1998).
19. Edwards, D. J., Bellevue, F. H. 3rd & Woster, P. M. Identification of 6′, 7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug. Metab. Dispos. 24, 1287-1290 (1996).
20. Veronese, M. L. et al. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J. Clin. Pharmacol. 43, 831-839 (2003).
21. Lin, J. H. & Yamazaki, M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 42, 59-98 (2003). A comprehensive review of P-glycoprotein and its effects on pharmacokinetics.
22. Balayssac, D., Authier, N., Cayre, A. & Coudore, F. Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol. Lett. 156, 319-329 (2005).
23. Zhou, S., Lim, L. Y. & Chowbay, B. Herbal modulation of P-glycoprotein. Drug Metab. Rev. 36, 57-104 (2004).
24. Martin-Facklam, M. et al. Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL. Br. J. Clin. Pharmacol. 53, 576-581 (2002).
25. Tayrouz, Y. et al. Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin. Pharmacol. Ther. 73, 397-405 (2003).
26. Woodcock, D. M. et al. Reversal of multidrug resistance by surfactants. Br. J. Cancer 66, 62-68 (1992).
27. van Zuylen, L., Verweij, J. & Sparreboom, A. Role of formulation vehicles in taxane pharmacology. Invest. New Drugs 19, 125-141 (2001).
28. Lepper, E. R. et al. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 6, 115-138 (2005).
29. Kivisto, K. T., Niemi, M. & Fromm, M. F. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam. Clin. Pharmacol. 18, 621-626 (2004).
30. Benet, L. Z. & Hoener, B. A. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther. 71, 115-121 (2002).
31. Lin, J. H. & Lu, A. Y. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 35, 361-390 (1998).
32. Dresser, G. K., Spence, J. D. & Bailey, D. G. Pharmacokinetic- pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38, 41-57 (2000).
33. Lehmann, J. M. et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102, 1016-1023 (1998).
34. Bertilsson, G. et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl Acad. Sci. USA 95, 12208-12213 (1998).
35. Kliewer, S. A. et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92, 73-82 (1998).
36. Wang, H. & LeCluyse, E. L. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet. 42, 1331-1357 (2003).
37. Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakoski, P. & Negishi, M. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J. Biol. Chem. 274, 6043-6046 (1999).
38. Blower, P., de Wit, R., Goodin, S. & Aapro, M. Drug-drug interactions in oncology: Why are they important and can they be minimized? Crit. Rev. Oncol. Hematol. 55, 117-142 (2005).
39. Roche Laboratories. Kytril prescribing information. Roche [online], http://www.rocheusa.com/products/kytril/pi_tablets.pdf (2005).
40. Sanwald, P., David, M. & Dow, J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab. Dispos. 24, 602-609 (1996).
41. Cagnoni, P. J. et al. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant. 24, 1-4 (1999).
42. Gilbert, C. J. et al. Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. Cancer Chemother. Pharmacol. 42, 497-503 (1998).
43. Gralla, R. J. et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J. Clin. Oncol. 17, 2971-2994 (1999).
44. OSI Pharmaceuticals Inc. & Genentech Inc. Tarceva prescribing information. Genentech [online], http://www.gene.com/gene/products/information/ oncology/tarceva/insert.jsp (2005).
45. Kobayashi, K. et al. A phase I study of CYP3A4 modulation of oral etoposide with ketoconazole in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 15, a1489 (1996).
46. Swaisland, H., Smith, R. P., Farebrother, J. & Laight, A. The effect of the induction and inhibition of CYP3A4 on the pharmacokinetics of single oral doses of ZD1839 ('Iressa'), a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in healthy male volunteers. Proc. Am. Soc. Clin. Oncol. 21, 83a (2002).
47. Ernst, E. & Cassileth, B. R. The prevalence of complementary/ alternative medicine in cancer: a systematic review. Cancer 83, 777-782 (1998).
48. Xie, H. G. & Kim, R. B. St John's wort-associated drug interactions: short-term inhibition and long-term induction? Clin. Pharmacol. Ther. 78, 19-24 (2005).
49. Burk, O. et al. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J. Biol. Chem. 279, 38379-38385 (2004).
50. Moore, L. B. et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl Acad. Sci. USA 97, 7500-7502 (2000).
51. Durr, D. et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin. Pharmacol. Ther. 68, 598-604 (2000).
52. Mathijssen, R. H., Verweij, J., de Bruijn, P., Loos, W. J. & Sparreboom, A. Effects of St. John's wort on irinotecan metabolism. J. Natl Cancer. Inst. 94, 1247-1249 (2002). The first clinical evaluation that showed a clinically significant interaction between a herbal supplement and chemotherapy.
53. Ciotti, M., Basu, N., Brangi, M. & Owens, I. S. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem. Biophys. Res. Commun. 260, 199-202 (1999).
54. Santos, A. et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin. Cancer Res. 6, 2012-2020 (2000).
55. Antoniou, T. & Tseng, A. L. Interactions between antiretrovirals and antineoplastic drug therapy. Clin. Pharmacokinet. 44, 111-145 (2005). A comprehensive review of potential drug interactions between anti-retrovirals and chemotherapy agents.
56. Huang, L. et al. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab. Dispos. 29, 754-760 (2001).
57. Schwartz, J. D., Howard, W. & Scadden, D. T. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi's sarcoma. Aids 13, 283-284 (1999).
58. Leveque, D. & Maloisel, F. Clinical pharmacokinetics of imatinib mesylate. In Vivo 19, 77-84 (2005).
59. Novartis Pharmaceuticals Corporation. Gleevec product information. Novartis [online], http://www.pharma.us.novartis.com/product/pi/pdf/ gleevec_tabs.pdf (2005).
60. Frye, R. F., Fitzgerald, S. M., Lagattuta, T. F., Hruska, M. W. & Egorin, M. J. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin. Pharmacol. Ther. 76, 323-329 (2004).
61. Dutreix, C. et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother. Pharmacol. 54, 290-294 (2004).
62. Ingelman-Sundberg, M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5, 6-13 (2005).
63. Crewe, H. K., Ellis, S. W., Lennard, M. S. & Tucker, G. T. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 53, 8 (1997).
64. Coezy, E., Borgna, J. L. & Rochefort, H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 42, 317-323 (1982).
65. Desta, Z., Ward, B. A., Soukhova, N. V. & Flockhart, D. A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310, 1062-1075 (2004).
66. Stearns, V. et al. Hot flushes. Lancet 360, 1851-1861 (2002).
67. Jin, Y. et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer. Inst. 97, 30-39 (2005).
68. Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K. & Sadee, W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286, 2270-2279 (2001).
69. Boddy, A. V. & Yule, S. M. Metabolism and pharmacokinetics of oxazaphosphorines. Clin. Pharmacokinet. 38, 291-304 (2000).
70. Chang, T. K., Weber, G. F., Crespi, C. L. & Waxman, D. J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53, 5629-5637 (1993).
71. Arboix, M., Paz, O. G., Colombo, T. & D'Incalci, M. Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis. J. Pharmacol. Exp. Ther. 281, 1226-1230 (1997).
72. Marsh, S. & McLeod, H. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 5, 835-843 (2004).
73. Yoshikawa, M. et al. Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J. Exp. Ther. Oncol. 4, 25-35 (2004).
74. Veronese, M. L. et al. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br. J. Cancer 92, 1846-1849 (2005).
75. Iacono, L. C. et al. Effect of gefitinib on the systemic disposition of intravenous irinotecan (IRN) in pediatric patients with refractory solid tumors. Proc. Am. Soc. Clin. Oncol. 22, a2011 (2004).
76. Ozvegy-Laczka, C. et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol. 65, 1485-1495 (2004).
77. Wierdl, M. et al. Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance. Mol. Pharmacol. 64, 279-288 (2003).
78. Kim, R. B. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur. J. Clin. Invest 33 (Suppl. 2), 1-5 (2003).
79. Marzolini, C., Tirana, R. G. & Kim, R. B. Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 5, 273-282 (2004).
80. Mikkaichi, T., Suzuki, T., Tanemoto, M., Ito, S. & Abe, T. The organic anion transporter (OATP) family. Drug Metab. Pharmacokinet 19, 171-179 (2004).
81. Smith, N. F., Acharya, M. R., Desai, N., Figg, W. D. & Sparreboom, A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer. Biol. Ther. 4, e5-e8 (2005).
82. Takeda, M. et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J. Pharmacol. Exp. Ther. 302, 666-671 (2002).
83. Dean, R., Nachman, J. & Lorenzana, A. N. Possible methotrexate-mezlocillin interaction. Am. J. Pediatr. Hematol. Oncol. 14, 88-89 (1992).
84. Frenia, M. L. & Long, K. S. Methotrexate and nonsteroidal antiinflammatory drug interactions. Ann. Pharmacother. 26, 234-247 (1992).
85. Baker, H. Intermittent high dose oral methotrexate therapy in psoriasis. Br. J. Dermatol. 82, 65-69 (1970).
86. Machover, D. et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study. Cancer Treat. Rep. 66, 1803-1807 (1982).
87. Morgan, R. G. Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase. Cancer 63, 1008-1012 (1989).
88. Kohne, C. H. et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J. Clin. Oncol. 21, 3721-3728 (2003).
89. Shiloni, E. & Matzner, Y. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: does it reduce the antitumor therapeutic efficacy? Blood 78, 1389-1390 (1991).
90. Mier, J. W. et al. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 76, 1933-1940 (1990).
91. Vetto, J.T., Papa, M. Z., Lotze, M. T., Chang, A. E. & Rosenberg, S. A. Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J. Clin. Oncol. 5, 496-503 (1987).
92. Papa, M. Z., Vetto, J. T., Ettinghausen, S. E., Mule, J. J. & Rosenberg, S. A. Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice. Cancer Res. 46, 5618-5623 (1986).
93. Seidman, A. et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin.Oncol. 20, 1215-1221 (2002).
94. Haas, A., Anderson, L. & Lad, T. The influence of aminoglycosides on the nephrotoxicity of cis-diamminedichloroplatinum in cancer patients. J. Infect. Dis. 147, 363 (1983).
95. Christensen, M. L., Stewart, C. F. & Crom, W. R. Evaluation of aminoglycoside disposition in patients previously treated with cisplatin. Ther. Drug Monit. 11, 631-636 (1989).
96. Bergstrom, P., Johnsson, A., Cavallin-Stahl, E., Bergenheim, T. & Henriksson, R. Effects of cisplatin and amphotericin B on DNA adduct formation and toxicity in malignant glioma and normal tissues in rat. Eur. J. Cancer 33, 153-159 (1997).
97. Genentech, Inc. Rituxan product information. Genentech [online], http://www.gene.com/gene/products/information/pdf/rituxan-pre scribing.pdf (2001).
98. Scalone, S. et al. Vinorelbine-induced acute reversible peripheral neuropathy in a patient with ovarian carcinoma pretreated with carboplatin and paclitaxel. Acta. Oncol. 43, 209-211 (2004).
99. Pierre-Fabre Pharmaceuticals. Navelbine prescribing information. Pierre-Fabre Pharmaceuticals [online], http://www.pierre-fabre.com/us/file/ nvb_prescribing_info_us.pdf (2005).
100. Parimoo, D., Jeffers, S. & Muggia, F. M. Severe neurotoxicity from vinorelbine-paclitaxel combinations. J. Natl Cancer. Inst. 88, 1079-1080 (1996).
101. Huizing, M. T. et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J. Clin. Oncol. 15, 317-329 (1997).
102. Baker, A. F. & Dorr, R. T. Drug interactions with the taxanes: clinical implications. Cancer Treat. Rev. 27, 221-233 (2001). A comprehensive review of potential drug interactions with anticancer agents that are classified as taxanes.
103. Baker, S. D. Drug interactions with the taxanes. Pharmacotherapy 17, 126S-132S (1997).
104. Bookman, M. A. et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J. Clin. Oncol. 14, 1895-1902 (1996).
105. Belani, C. P. et al. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J. Clin. Oncol. 17, 676-684 (1999).
106. Vaughn, D., Mick, R., Ratajczak, J., Ratajczak, M. K. & Gewirtz, A. Investigating the platelet sparing mechanism of paclitaxel/carboplatin chemotherapy. Proc. Am. Soc. Clin. Oncol. 16, 897a (1997).
107. Nabholtz, J. M. & Riva, A. Taxane/anthracycline combinations: setting a new standard in breast cancer? Oncologist 6 (Suppl. 3), 5-12 (2001).
108. Venturini, M. et al. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. J. Clin. Oncol. 18, 2116-2125 (2000).
109. Holmes, F. A. et al. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J. Clin. Oncol. 14, 2713-2721 (1996).
110. Lederle Parenterals. Methotrexate Prescribing Information. US Food and Drugs Administration [online], http://www.fda.gov/medwatch/SAFETY/2004/jan_PI/ Methotrexate_Pl.pdf (1999).
111. Relling, M. V. et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 356, 285-290 (2000).
112. Thorn, C. F. et al. Irinotecan pathway. PharmGKB [online], http://www.pharmgkb.org/search/pathway/irinotecan/liver.jsp (2005).
113. Kehrer, D. F., Mathijssen, R. H., Verweij, J., de Bruijn, P. & Sparreboom, A. Modulation of irinotecan metabolism by ketoconazole. J. Clin. Oncol. 20, 3122-3129 (2002).
114. Schuler, U. et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 14, 759-765 (1994).
115. Janish, L., Mani, S. & Schilsky, R. L. Phase I study to determine the effects of food on the absorption of oral 776C85 (776) plus 5-fluorouracil (FU) in patients (pts) with advanced cancer [abstract]. 34th Annu. Meeting Am. Soc. Clin. Oncol. 16-19 May, A862 (1998).
116. Pinkerton, C. R., Welshman, S. G., Glasgow, J. F. & Bridges, J. M. Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia? Lancet 2, 944-946 (1980).
117. Herben, V. M. et al. Oral topotecan: bioavailablity and effect of food co-administration. Br. J. Cancer 80, 1380-1386 (1999).
118. Barker, I. K., Crawford, S. M. & Fell, A. F. Determination of altretamine in human plasma with high-performance liquid chromatography. J. Chromatogr.660, 121-126 (1994).
119. Swaisland, H. et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin. Pharmacokinet. 40, 297-306 (2001).
120. Reece, P. A., Kotasek, D., Morris, R. G., Dale, B. M. & Sage, R. E. The effect of food on oral melphalan absorption. Cancer Chemother. Pharmacol. 16, 194-197 (1986).
121. Lancaster, D. L., Patel, N., Lennard, L. & Lilleyman, J. S. 6-Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations. Br. J. Clin. Pharmacol. 51, 531-539 (2001).
122. Usuki, K. et al. Pharmacokinetics of all-trans-retinoic acid in Japanese patients with acute promyelocytic leukemia. Int. J. Hematol. 63, 19-23 (1996).
123. Harvey, V. J., Slevin, M. L., Joel, S. P., Johnston, A. & Wrigley, P. F. The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide. Br. J. Cancer 52, 363-367 (1985).
124. Reckmann, A. H., Fischer, T. & Peng, B. Effect of food on STI571 pharmacokinetics and bioavailability [abstract]. 37th Annu. Meeting Am. Soc. Clin. Oncol 12-15 May 12-15, A1223 (2001).
125. Lonnerholm, G., Kreuger, A., Lindstrom, B. & Myrdal, U. Oral mercaptopurine in childhood leukemia: influence of food intake on bioavailability. Pediatr. Hematol. Oncol. 6, 105-112 (1989).
126. Brada, M. et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br. J. Cancer 81, 1022-1030 (1999).
127. Astra Zeneca Pharmaceuticals. Arimidex Prescribing Information. Astra Zeneca [online], http://www.astrazeneca-us.com/pi/arimidex.pdf (2005).
128. Buggia, I. et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res. 16, 2083-2088 (1996).
129. Merck & Co. Decadron prescribing information. Merck [online], http://www.merck.com/product/usa/pi_circulars/d/decadron/decadron_tbl ts_pi.pdf (2004).
130. Chang, T. K., Yu, L., Maurel, P. & Waxman, D. J. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 57, 1946-1954 (1997).
131. Colburn, D. E., Giles, F. J., Oladovich, D. & Smith, J. A. In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology 9, 217-221 (2004).
132. Hirth, J. et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin. Cancer Res. 6, 8 (2000).
133. Royer, I., Monsarrat, B., Sonnier, M., Wright, M. & Cresteil, T. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res. 56, 58-65 (1996).
134. Kivisto, K. T., Kroemer, H. K. & Eichelbaum, M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br. J. Clin. Pharmacol. 40, 523-530 (1995).
135. Zhuo, X., Zheng, N., Felix, C. A. & Blair, I. A. Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab. Dispos. 32, 993-1000 (2004).
136. Pharmacia & Upjohn Co. Aromasin prescribing information. Pfizer [online], http://www.pfizer.com/pfizer/download/uspi_aromasin.pdf (2005).
137. Astra Zeneca Pharmaceuticals. Iressa prescribing information. Astra Zeneca Pharmaceuticals [online], http://www.astrazeneca-us.com/pi/iressa.pdf (2005).
138. Kaijser, G. P., Korst, A., Beijnen, J. H., Bult, A. & Underberg, W. J. The analysis of ifosfamide and its metabolites (review). Anticancer Res. 13, 1311-1324 (1993).
139. Zhang, W. et al. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab. Dispos. 30, 314-318 (2002).
140. Novartis Pharmaceuticals Corporation. Femara prescribing information. Novartis Pharmaceuticals [online], http://www.pharma.us.novartis.com/product/pi/ pdf/Femara.pdf (2005).
141. Harris, J. W., Rahman, A., Kim, B. R., Guengerich, F. P. & Collins, J. M. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54, 4026-4035 (1994).
142. Rahman, A., Korzekwa, K. R., Grogan, J., Gonzalez, F. J. & Harris, J. W. Selective biotransformation of taxol to 6 α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54, 5543-5546 (1994).
143. Sridar, C., Kent, U. M., Notley, L. M., Gillam, E. M. & Hollenberg, P. F. Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J. Pharmacol. Exp. Ther. 301, 52 (2002).
144. Jordan, V. C., Collins, M. M., Rowsby, L. & Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 75, 305-316 (1977).
145. Roche Laboratories. Vesanoid prescribing information. Roche [online], http://www.rocheusa.com/products/vesanoid/pi.pdf (2004).
146. Zhou, X. J., Placidi, M. & Rahmani, R. Uptake and metabolism of vinca alkaloids by freshly isolated human hepatocytes in suspension. Anticancer Res. 14, 1017-1022 (1994).
147. Lam, M. S. H. & Ignoffo, R. J. A guide to clinically relevant drug interactions in oncology. J. Oncol. Pharm. Practice 9, 45-85 (2003). A comprehensive review in tabular format on actual and theoretical drug interactions in oncology.
148. Innocenti, F. et al. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin. Pharmacol. Ther. 76, 490-502 (2004).
149. Yong, W. P., Ramirez, J., Innocenti, F. & Ratain, M. J. Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin. Cancer. Res. 11, 6699-6704 (2005).
150. Friedman, H. S. et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol. 17, 1516-1525 (1999).